Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Analysis of Quality-of-Life (QoL) in Patients Receiving NEPA for Prevention of Chemotherapy-Induced Nausea (CINV) and Vomiting

Meinolf Karthaus, MD, M O Zahn, B Tschechne, B. Gerber, S Haas, U Schwindel, M Konias, A R Rotmann, J Schilling

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-135916

Published: 2020

Journal Articles

Invasive Mucormycosis in Patients with Hematological Diseases Identified in the Global Fungiscope Registry

Meinolf Karthaus, MD, Luisa Duran Graeff, MD, Maria J.G.T. Vehreschild, MD, Arne Meißner, MD, Jon Salmanton-Garcia, Philipp Köhler, MD, Hilmar Wisplinghoff, MD, J. Janne Vehreschild, MD, Oliver Cornely, MD, Danila Seidel, PhD

Blood (2017) 130 (Supplement 1): 5649.

https://doi.org/10.1182/blood.V130.Suppl_1.5649.5649

Published: 2017

Journal Articles

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Meinolf Karthaus, MD, P Klare, V Heilmann, G Klausmann, Joerg Schilling

Blood (2017) 130 (Supplement 1): 2180.

https://doi.org/10.1182/blood.V130.Suppl_1.2180.2180

Published: 2017

Journal Articles

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Meinolf Karthaus, MD, Matti Aapro, MD, Giada Rizzi, M.Sc., Marco Palmas, MD

Blood (2014) 124 (21): 4821.

https://doi.org/10.1182/blood.V124.21.4821.4821

Published: 2014

Journal Articles

Evidence Of Therapeutic Drug Monitoring (TDM) In The Treatment Of Invasive Aspergillosis (IA) With Voriconazole (VCZ) In Cancer Patients

Meinolf Karthaus, MD, Thomas Lehrnbecher, MD, Dieter Buchheidt

Blood (2013) 122 (21): 2977.

https://doi.org/10.1182/blood.V122.21.2977.2977

Published: 2013

Journal Articles

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Lee Schwartzberg, MD, FACP, Cristina Oprean, MD, Servando Cardona-Huerta, MD, Giada Rizzi, M.Sc., Giorgia Rossi, MD, Marco Palmas, MD, Meinolf Karthaus, MD, Matti Aapro, MD

Blood (2013) 122 (21): 2949.

https://doi.org/10.1182/blood.V122.21.2949.2949

Published: 2013

Journal Articles

Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.

Blood (2009) 114 (22): 4736.

https://doi.org/10.1182/blood.V114.22.4736.4736

Published: 2009

NARROW

Analysis of Quality-of-Life (QoL) in Patients Receiving NEPA for Prevention of Chemotherapy-Induced Nausea (CINV) and Vomiting

Invasive Mucormycosis in Patients with Hematological Diseases Identified in the Global Fungiscope Registry

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Evidence Of Therapeutic Drug Monitoring (TDM) In The Treatment Of Invasive Aspergillosis (IA) With Voriconazole (VCZ) In Cancer Patients

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.

Email alerts

ASH Publications

American Society of Hematology

Analysis of Quality-of-Life (QoL) in Patients Receiving NEPA for Prevention of Chemotherapy-Induced Nausea (CINV) and Vomiting

Invasive Mucormycosis in Patients with Hematological Diseases Identified in the Global Fungiscope Registry

Quality of Life and Patient Reported Outcome (PRO) in Patients Receiving High and Moderate Emetogenic Chemotherapy (Ctx) - Results of a German Non-Interventional Study with NEPA - a Netupitant/Palonosetron Fixed Dose Combination

Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy

Evidence Of Therapeutic Drug Monitoring (TDM) In The Treatment Of Invasive Aspergillosis (IA) With Voriconazole (VCZ) In Cancer Patients

No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron

Forty-One Recent Cases of Invasive Zygomycosis From a Global Clinical Registry.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only